Michael Brawer, MD, vice president, Medical Affairs, Myriad Genetic Laboratories, discusses Prolaris testing in men who have clinically localized prostate cancer.
Brawer describes how the Prolaris test helps to provide prognostic information in men with this disease. It determines who needs aggressive therapy from those who can handle conservative treatment and still do well.
Michael Brawer, MD, vice president, Medical Affairs, Myriad Genetic Laboratories, discusses Prolaris testing in men who have clinically localized prostate cancer.
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More